Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes of high-risk percutaneous coronary interventions under extracorporeal membrane oxygenation support: An observational study.

World journal of clinical cases·2022
Same author

AngioJet rheolytic thrombectomy in patients with thrombolysis in myocardial infarction thrombus grade 5: an observational study.

Scientific reports·2022
Same author

Prevalence and composition of CHD at different altitudes in Tibet: a cross-sectional study.

Cardiology in the young·2017
Same author

Transthoracic contrast echocardiography using vitamin B6 and sodium bicarbonate as contrast agents for the diagnosis of patent foramen ovale.

The international journal of cardiovascular imaging·2017
Same author

Resting Myocardial Contrast Echocardiography for the Evaluation of Coronary Microcirculation Dysfunction in Patients With Early Coronary Artery Disease.

Clinical cardiology·2016
Same author

Prevalence and predictors of decreased glomerular filtration rate in tibetan children with congenital heart disease.

Indian journal of pediatrics·2014

Related Experiment Video

Updated: Jun 9, 2026

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction
06:47

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction

Published on: July 25, 2025

AngioJet Rheolytic Thrombectomy Combined with Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction: An

Yi-Xiong Huang1,2, Yi Cao2, Yu Chen2

  • 1Medical School of Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Haidian District, Peking, 100853, People's Republic of China.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|June 8, 2026
PubMed
Summary

Combining AngioJet rheolytic thrombectomy with glycoprotein IIb/IIIa inhibitors (GPI) did not improve 1-year outcomes for ST-segment elevation myocardial infarction (STEMI) patients compared to routine treatment. This strategy did not increase bleeding or stroke risk.

Keywords:
STEMIpercutaneous coronary interventionplatelet glycoprotein IIb/IIIa inhibitorspropensity-score matchingthrombectomy

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: Jun 9, 2026

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction
06:47

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction

Published on: July 25, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Thrombosis Management

Background:

  • ST-segment elevation myocardial infarction (STEMI) requires rapid reperfusion.
  • AngioJet rheolytic thrombectomy is an option for thrombus removal.
  • Glycoprotein IIb/IIIa inhibitors (GPI) are used to prevent thrombotic complications.

Purpose of the Study:

  • To evaluate the efficacy and safety of AngioJet rheolytic thrombectomy with adjunctive GPI in STEMI patients.
  • To compare outcomes between AngioJet with GPI and routine treatment.

Main Methods:

  • Retrospective cohort study of 877 STEMI patients.
  • Propensity score matching (PSM) to balance baseline characteristics.
  • Primary endpoint: major adverse cardiovascular and cerebrovascular events (MACCE) at 1 year.
  • Safety endpoints: bleeding and stroke.

Main Results:

  • No significant differences in in-hospital mortality, reinfarction, stent thrombosis, stroke, or bleeding between groups.
  • After PSM, 1-year MACCE rates were similar (8.2% vs 9.3%; p=0.818).
  • No significant differences in individual safety endpoints, including bleeding and stroke.

Conclusions:

  • Combining AngioJet rheolytic thrombectomy with GPI in STEMI patients did not improve 1-year outcomes compared to routine treatment.
  • This combined strategy did not elevate the risk of bleeding or stroke.
  • Further research may explore optimized patient selection for this intervention.